Bayesian Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Bayesian Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-21,065	Closed	-$91K	–	1052
2023 Q3	$91K	Buy	+21,065	New	+$117K	0.01%	612
2020 Q1	–	Sell	-16,400	Closed	-$269K	–	993
2019 Q4	$269K	Buy	+16,400	New	+$248K	0.05%	456
2019 Q2	–	Sell	-13,100	Closed	-$241K	–	688
2019 Q1	$241K	Sell	13,100 -5,800	-31%	-$132K	0.05%	435
2018 Q4	$494K	Sell	18,900 -7,200	-28%	-$169K	0.1%	288
2018 Q3	$599K	Buy	26,100 +14,300	+121%	+$292K	0.1%	290
2018 Q2	$225K	Buy	+11,800	New	+$197K	0.05%	490

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Bayesian Capital Management's VNDA Position: Q4 2023 in Review

Bayesian Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 21,065 shares — an estimated $91K sold.

Bayesian Capital Management first reported a position in VNDA in Q2 2018 and held it in 6 quarters. The position peaked at $599K in Q3 2018. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

Bayesian Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Bayesian Capital Management sold 21,065 Vanda Pharmaceuticals shares in Q4 2023, an estimated $91K.
Bayesian Capital Management first reported a position in Vanda Pharmaceuticals in Q2 2018 and held it in 6 quarters.
Bayesian Capital Management's Vanda Pharmaceuticals position peaked at $599K in Q3 2018.
157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Bayesian Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.